The Role of Sugammadex for Neuromuscular Blockade Reversal in Neuro Critical Care Patients

Technical Summary: The Role of Sugammadex for Neuromuscular Blockade Reversal in Neuro Critical Care Patients

Problem Statement
In acute nontraumatic neurologic injury, the principle that "time is brain" necessitates rapid, reliable neurologic assessment to guide time-sensitive clinical and neurosurgical decisions. However, emergent intubation often requires the administration of neuromuscular blocking agents (NMBs), such as rocuronium or vecuronium, which can obscure neurologic findings and delay accurate severity assessment. While neostigmine has historically been used for reversal, it offers variable efficacy and delayed recovery. Sugammadex, a selective relaxant binding agent approved by the FDA in 2015 for perioperative reversal of aminosteroid NMBs, provides rapid and predictable reversal. Despite its established use in trauma and emergency department (ED) settings for traumatic brain injury (TBI), there is a significant gap in data regarding its efficacy and safety in nontraumatic neurocritical care patients. Existing literature largely focuses on traumatic populations or mixed ED cohorts, leaving the specific utility of sugammadex for facilitating neurologic examination in nontraumatic critical care (e.g., intracerebral hemorrhage, ischemic stroke, status epilepticus) underexplored.

Methodology
This study is a retrospective, single-center, observational cohort study conducted at the University of Tennessee Medical Center, a Level 1 Trauma and Comprehensive Stroke Center.

• Population: The study included 153 adult patients (≥18 years) with nontraumatic neurologic injuries (intracerebral hemorrhage, ischemic stroke, status epilepticus, or spontaneous head bleed) who received sugammadex for NMB reversal between April 2016 and December 2024. Patients with traumatic injuries, those receiving sugammadex solely for routine postoperative reversal, and pregnant patients were excluded.
• Data Collection: Researchers collected demographics, medical history, presenting Glasgow Coma Score (GCS), NMB agent details, intubation location, and sugammadex dosing.
• Dosing Stratification: Patients were categorized by sugammadex dose: high (>4 mg/kg), medium (2–4 mg/kg), and low (<2 mg/kg).
• Outcomes:
  • Primary Outcome: The impact of sugammadex on neurologic decision-making, defined as the escalation of care (e.g., emergent surgery, EVD placement, thrombectomy), de-escalation of care (e.g., transition to comfort-focused management), or a change in neurologic examination findings.
  • Secondary Outcomes: Adverse events (hypotension, bradycardia, hypersensitivity), cost, and GCS improvement within two hours of administration.
• Analysis: Statistical analysis utilized descriptive statistics and chi-square tests for subgroup comparisons (injury type, dosing strategy, intubation location). Significance was set at p < 0.05.

Key Results

• Clinical Decision-Making: Following sugammadex administration, nearly half of the cohort experienced a change in care trajectory.
  • Escalation of Care: 36 patients (23.5%) required escalation, most commonly involving neurosurgical interventions such as external ventricular drain (EVD) placement (14.4%), craniotomy/craniectomy (7.2%), or thrombectomy (6.5%).
  • De-escalation of Care: 38 patients (24.8%) underwent de-escalation. Notably, 29 patients (19%) were transitioned to comfort-based management after reversal clarified the neurologic prognosis.
• Safety Profile: Sugammadex demonstrated a favorable safety profile. No neurologic deterioration was attributed to the drug.
  • Adverse events were infrequent: Hypotension occurred in 13.7% of patients, and bradycardia in 11.1%.
  • 64.1% of patients experienced no documented adverse events.
• Subgroup Analysis: No statistically significant differences were found in escalation or de-escalation outcomes based on:
  • Neurologic injury type (hemorrhagic vs. ischemic).
  • Sugammadex dosing strategies (<2 mg/kg, 2–4 mg/kg, ≥4 mg/kg).
  • Intubation location (EMS/outside hospital vs. in-house).
• Neurologic Recovery: The median best GCS within two hours post-reversal was 7 (IQR 5–8).

Significance and Claims
The authors claim that this study represents one of the largest cohorts to date evaluating sugammadex specifically for neurologic examination in nontraumatic neurocritical care patients, expanding beyond the previously documented trauma and ED populations.

The paper asserts that sugammadex facilitates timely and accurate neurologic reassessment, which directly influences critical management decisions. The findings support the dual utility of the drug in this setting:

1. Identifying Candidates for Intervention: Reversal allows for the detection of patients who may benefit from time-sensitive neurosurgical or neurointerventional procedures (escalation).
2. Prognostication and Goals of Care: Crucially, the study highlights that reversal also aids in identifying patients with poor neurologic recovery, thereby supporting informed decisions to transition to comfort-focused care (de-escalation).

The authors conclude that sugammadex is a safe and effective strategy for facilitating neurologic assessment in nontraumatic neurocritical care, particularly in settings where train-of-four (TOF) monitoring may not be feasible. They emphasize that the observed changes in care were reflective of the underlying injury severity revealed by the reversal, rather than adverse effects of the agent. The study calls for future prospective research to further define optimal dosing strategies and evaluate cost-effectiveness, while maintaining that current real-world data supports its use for expediting clinical decision-making.